Type 1 diabetes is caused by an immune system attack on the insulin-producing cells in the pancreas. For reasons that involve both genetics and environmental triggers, the body’s own immune cells mistakenly identify these beta cells as foreign and destroy them over months or years. By the time symptoms appear, a significant portion of beta cells are already gone, leaving the body unable to produce enough insulin to regulate blood sugar.
This process isn’t sudden. It unfolds in stages, often beginning years before a person feels anything wrong. Understanding what sets it off requires looking at several factors working together.
The Autoimmune Process Behind It
In a healthy immune system, white blood cells attack bacteria, viruses, and other invaders while leaving the body’s own tissue alone. In type 1 diabetes, that distinction breaks down. The immune system produces autoantibodies, proteins that target the body’s own beta cells in clusters called islets, located in the pancreas. These beta cells are the only cells in the body that make insulin, the hormone that moves sugar from the bloodstream into cells for energy.
Researchers have identified four main autoantibodies involved. Roughly 50% to 80% of people with type 1 diabetes test positive for one targeting an enzyme called GAD at the time of diagnosis. Others target proteins on the surface of beta cells or insulin itself. The number of autoantibodies a person carries matters enormously for predicting the disease: someone with two or more has about a 70% chance of developing clinical type 1 diabetes within 10 years, and the risk approaches 100% over a lifetime. With three or more, nearly 75% progress within 10 years. A single autoantibody, by contrast, carries only about a 15% chance over the same period.
Genetic Risk Factors
Genes don’t guarantee type 1 diabetes, but they heavily influence who is vulnerable. A specific region of DNA involved in immune function accounts for roughly 40% of the inherited risk. The highest-risk genetic profile involves inheriting two particular immune system gene variants, one from each parent. Siblings who share this full genetic profile with a brother or sister who already has type 1 diabetes face dramatically elevated risk: 55% developed the disease by age 12 in one study, compared to just 5% of siblings who didn’t share those genes.
Even among siblings with the highest-risk combination, 85% showed signs of immune activity against their beta cells by age 15. But genetics alone doesn’t tell the whole story. Most people diagnosed with type 1 diabetes have no family history of the condition, and plenty of people carry high-risk genes without ever developing it. Something in the environment has to pull the trigger.
Viral and Environmental Triggers
Several viruses have been linked to the onset of the autoimmune process, with a family of gut viruses called enteroviruses drawing the most attention. Detecting viral genetic material in the blood has been associated with the development of autoimmunity against beta cells, sometimes with a gap of several months between the infection and the first signs of immune attack. Different strains appear to carry different levels of risk. One strain, Coxsackievirus B4, has been shown to impair the body’s ability to handle glucose in animal studies, while a closely related strain, B3, did not. Coxsackievirus B1 has also been flagged in large population surveys across Europe as a risk factor.
These viruses likely don’t cause type 1 diabetes on their own. Instead, they may kick-start the immune response in someone who is already genetically susceptible, perhaps by damaging beta cells just enough to expose them to the immune system or by creating inflammation that confuses immune cells into attacking the wrong target.
The Role of Early Microbial Exposure
One of the more striking clues about environmental causes comes from comparing populations that are genetically similar but live in very different conditions. The prevalence of type 1 diabetes is six times lower in Russian Karelia than in neighboring Finland, despite both populations carrying similar frequencies of the genetic risk factors for the disease. The key difference appears to be the microbial environment children grow up in.
A Harvard Medical School study found that Finnish and Estonian infants had gut bacteria dominated by a species called Bacteroides, while Russian Karelian infants had more Bifidobacterium and a wider variety of microbes overall. The Bacteroides-dominant gut microbiome turned out to be, in the researchers’ words, “immunologically very silent.” It produced molecules that actually dampened immune activation rather than training the immune system to distinguish friend from foe. The researchers concluded that this lack of early immune education may leave children more prone to the kind of overactive inflammatory response that leads to autoimmune disease later.
This aligns with the broader hygiene hypothesis: that the cleaner, more sanitized environments in wealthy countries may inadvertently deprive developing immune systems of the microbial exposure they need to calibrate properly. It’s not that dirt prevents diabetes, but that a diverse microbial environment in early life helps the immune system learn what to attack and what to leave alone.
How Type 1 Diabetes Develops in Stages
Type 1 diabetes doesn’t appear overnight. Researchers now define three distinct stages, a framework that has changed how the disease is understood and, increasingly, how it’s treated.
In Stage 1, the immune attack has begun and autoantibodies are detectable in the blood, but blood sugar levels are still completely normal. There are no symptoms. A person can remain in this stage for years without knowing anything is happening. Stage 2 looks similar, with two or more autoantibodies present, but enough beta cells have been destroyed that blood sugar levels start to become abnormal. There are still no noticeable symptoms at this point. Stage 3 is the clinical diagnosis most people think of: significant beta cell loss, elevated blood sugar, and the classic symptoms of extreme thirst, frequent urination, weight loss, and fatigue.
Younger age at the time autoantibodies first appear and having a higher number of autoantibodies are both associated with faster progression through these stages.
Delaying the Disease in High-Risk People
The staging framework has opened a new window for intervention. In 2024, the UK approved the first medication designed to delay the onset of clinical type 1 diabetes in people identified at Stage 2. The treatment is a 14-day course of daily infusions that targets the immune cells responsible for destroying beta cells. In clinical trials, it delayed progression to Stage 3 by an average of three years.
Three years may not sound like much in the abstract, but for a child or teenager, it can mean years free from daily insulin injections, blood sugar monitoring, and the constant management the disease demands. It also represents a fundamental shift: for the first time, a treatment targets the autoimmune cause of type 1 diabetes rather than managing the consequences after beta cells are already gone.